• Reuters

  • SHARE

Pfizer Inc and BioNTech SE on Tuesday submitted initial trial data for their COVID-19 vaccine in five to 11-year-olds and said they would make a formal request to U.S. regulators for emergency use in the coming weeks.

The U.S. Food and Drug Administration said earlier this month it would look to complete its data review for this age group as quickly as possible, likely in a matter of weeks rather than months.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)